1,673 material Form 8-K filings that 1,260 companies we cover made with the SEC in February 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
FTI Consulting reported record fourth-quarter 2025 revenue of $990.7 million, up 10.7%, and full-year revenue of $3.789 billion, up 2.4%. Fourth-quarter EPS rose to $1.78 from $1.38 despite a $0.38 per-share charge for a valuation allowance on prior-year foreign deferred tax assets, and the company introduced 2026 guidance of $3.940 billion to $4.100 billion in revenue and $8.90 to $9.60 in EPS.
Q4 2025 revenue of $990.7 million, up from $894.9 million; diluted EPS of $1.78 versus $1.38 a year earlier
Full-year 2025 diluted EPS of $8.24 versus $7.81; full-year net income of $270.9 million versus $280.1 million
2026 guidance: revenue of $3.940 billion to $4.100 billion and EPS of $8.90 to $9.60
Repurchased $858.6 million of common stock in 2025; about $491.8 million remained under the buyback program at December 31, 2025
DTE Energy furnished audited 2025 financial statements for its indirect subsidiary DTE Gas Company, which show higher revenue and net income than in 2024. The filing is a subsidiary disclosure and does not change DTE Energy's own guidance, but it shows the gas utility's growth and a pending rate request that could raise its base rates.
Operating revenues were $2,033 million in 2025, up $250 million from $1,783 million in 2024, mainly from weather ($119 million) and gas cost recovery ($111 million).
Net income was $296 million in 2025, compared with $259 million in 2024; operating income was $498 million, compared with $438 million.
DTE Gas filed a rate case on November 13, 2025, requesting a net base rate increase of $163 million and a return on equity increase from 9.8% to 10.25%; a final MPSC order is expected in September 2026.
PricewaterhouseCoopers LLP issued an unqualified audit opinion dated February 27, 2026.
PrimeEnergy Resources signed a Fifth Amendment to its senior secured revolving credit agreement on February 24, 2026, as part of a scheduled borrowing base redetermination. The borrowing base was reaffirmed at $115.0 million, and the full amount was available with no borrowings outstanding as of February 27, 2026. The amendment lowers loan margins by 50 basis points, which reduces borrowing costs if the company draws on the facility.
Borrowing base reaffirmed at $115.0 million effective February 24, 2026
SOFR loan margin now 2.75% to 3.75%, down from 3.25% to 4.25%
Commodity hedging covenant utilization threshold raised from 25% to 30%
No borrowings outstanding as of February 27, 2026; full $115.0 million available
National HealthCare Corporation reported results for the year and quarter ended December 31, 2025, in a press release furnished under Item 2.02. Full-year net operating revenues and grant income rose 16.1% to $1.5 billion, and GAAP net income attributable to NHC rose to $120.0 million from $101.9 million. For shareholders, both revenue and reported profit increased, though the filing notes that the year's GAAP results include unrealized gains on marketable equity securities.
FY2025 net operating revenues and grant income: $1,517,781,000, up from $1,307,382,000 in 2024
FY2025 GAAP net income attributable to NHC: $120,015,000 (diluted EPS $7.67), up from $101,927,000 in 2024
FY2025 adjusted diluted EPS: $6.65, compared with $4.93 in 2024
Q4 2025 GAAP diluted EPS: $1.58, compared with $0.39 in Q4 2024; Q4 adjusted diluted EPS: $1.83, compared with $1.66
Assured Guaranty Ltd. filed audited 2025 combined financial statements for its subsidiary Assured Guaranty Inc. and posted them on its website, along with a financial supplement and a fixed income investor presentation. The subsidiary reported total revenues of $806 million for 2025, up from $668 million in 2024, and net income attributable to Assured Guaranty Inc. of $437 million, up from $402 million. The filing covers the subsidiary only, not the parent's consolidated results.
Total revenues were $806 million in 2025, compared with $668 million in 2024.
Net income attributable to Assured Guaranty Inc. was $437 million in 2025, compared with $402 million in 2024.
Dividends paid to the parent were $287 million in 2025, compared with $400 million in 2024.
Total shareholder's equity was $5,485 million as of December 31, 2025, compared with $5,376 million a year earlier.
NIQ Global Intelligence reported fourth-quarter 2025 revenue of $1,139.1 million, up 9.2% year over year, and full-year revenue of $4,198.4 million, up 5.7%. The net loss attributable to NIQ narrowed to $32.2 million in the quarter and $353.3 million for the year, and the company introduced 2026 guidance along with a cost program that carries $50 million to $60 million of pre-tax restructuring charges.
Q4 2025 net loss attributable to NIQ was $32.2 million, compared with $172.9 million in Q4 2024.
Full-year 2025 adjusted EBITDA was $916.5 million, up 23.8%, and the adjusted EBITDA margin was 21.8%.
2026 full-year guidance calls for as-reported revenue of $4,439 million to $4,452 million and adjusted EBITDA of $1,043 million to $1,060 million.
In February 2026 the company approved a cost program expected to generate $55 million to $65 million of annualized savings by the end of 2026.
ANI Pharmaceuticals reported record fourth-quarter and full-year 2025 results, with Q4 net revenue of $247.1 million and GAAP net income available to common shareholders of $27.5 million, compared with a loss in the prior-year quarter. The company reaffirmed its full-year 2026 guidance, including total net revenue of $1,055 million to $1,115 million, which matters to shareholders as a reaffirmation rather than a change in outlook.
Q4 2025 net revenue was $247.1 million, up 29.6%; Cortrophin Gel rose 87.6% to $111.4 million, while Brands fell 37.9% to $12.3 million
Q4 GAAP diluted EPS was $1.18 versus a loss of $0.55 a year earlier; adjusted non-GAAP diluted EPS was $2.33 versus $1.63
Full-year 2025 net revenue was $883.4 million, up 43.8%, with GAAP net income available to common shareholders of $77.2 million
2026 guidance reaffirmed: total net revenue $1,055 million to $1,115 million and adjusted non-GAAP diluted EPS $8.83 to $9.34
Amneal Pharmaceuticals reported fourth-quarter 2025 net revenue of $814 million, up 11% from a year earlier, and GAAP net income attributable to the company of $35 million, compared with a loss of $31 million in the fourth quarter of 2024. For the full year, revenue rose 8% to $3.02 billion and adjusted diluted EPS was $0.83, and the company gave 2026 guidance of $3.05 billion to $3.15 billion in net revenue and $0.93 to $1.03 in adjusted diluted EPS, which is above 2025 results.
Q4 2025 net revenue was $814 million, up 11%, with Specialty up 38% and Affordable Medicines down 1%
Q4 2025 GAAP diluted EPS was $0.11 versus a loss of $0.10 a year earlier; adjusted diluted EPS was $0.21 versus $0.12
Full year 2025 net revenue was $3.02 billion and adjusted EBITDA was $688 million, up 10%
2026 guidance: net revenue of $3.05 billion to $3.15 billion, adjusted EBITDA of $720 million to $760 million, adjusted diluted EPS of $0.93 to $1.03
BrightSpring reported fourth-quarter 2025 revenue of $3,551 million, up 29.3%, and net income from continuing operations of $49.6 million, up from $4.3 million a year earlier. The company also initiated full-year 2026 revenue guidance of $14,450 million to $15,000 million and Adjusted EBITDA guidance of $760 million to $790 million, both excluding the Community Living business.
Q4 2025 Adjusted EBITDA was $184 million, up 40.7% from $130 million; full-year 2025 Adjusted EBITDA was $618 million, up 34.2%.
Full-year 2025 net income from continuing operations was $104.8 million, compared with a net loss of $68.9 million in 2024.
Leverage fell to 2.99x at December 31, 2025, from 4.16x a year earlier.
The Community Living divestiture to Sevita is expected to close by the end of the first quarter of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.